ライフサイエンスコーパス: fatal outcome

1 nformation on the management of cases with a fatal outcome.

2 onatal multisystem disease and have an early fatal outcome.

3 P = .022) were significantly associated with fatal outcome.

4 e clinically severe presentation and rapidly fatal outcome.

5 nd pharyngeal specimens were associated with fatal outcome.

6 ated blood creatine kinase levels, and early fatal outcome.

7 s with prominent pulmonary involvement and a fatal outcome.

8 tion demonstrated JCV, and she had a rapidly fatal outcome.

9 he respiratory tract, to severe disease with fatal outcome.

10 entlessly progressive conditions that have a fatal outcome.

11 in hospitalization of two patients, with one fatal outcome.

12 sis are the best independent predictors of a fatal outcome.

13 ly occluded the coronary orifice, leading to fatal outcome.

14 disease (EVD), with high values leading to a fatal outcome.

15 eightfold during therapy, and the case had a fatal outcome.

16 day 1 a 12-fold increased relative risk of a fatal outcome.

17 d and on day 6 a nine-fold increased risk of fatal outcome.

18 ogressive neurologic disease and an eventual fatal outcome.

19 e brain is the target organ and produces the fatal outcome.

20 nique virus genomic mutation associated with fatal outcome.

21 was no association between TNF genotype and fatal outcome.

22 Metastatic cancer in adults usually has a fatal outcome.

23 mpanied by progressive pulmonary opacity and fatal outcome.

24 ve clinical syndrome of unknown etiology and fatal outcome.

25 underlying liver disease was associated with fatal outcome.

26 n (P < .01) was positively associated with a fatal outcome.

27 the time of infection were protected from a fatal outcome.

28 r factors that may alter the likelihood of a fatal outcome.

29 respiratory pathogen was not associated with fatal outcome.

30 ek timeframe, needing intensive care or with fatal outcome.

31 volved a life threatening event, or led to a fatal outcome.

32 e of inflicting neurological infections with fatal outcome.

33 insulin with constant monitoring to avoid a fatal outcome.

34 and thrombotic complications, and sometimes fatal outcome.

35 ective hemostasis strongly correlated with a fatal outcome.

36 nique virus genomic mutation associated with fatal outcome.

37 monogenic immune disorders with an otherwise fatal outcome.

38 nflammation, tissue hypoperfusion, MODS, and fatal outcome.

39 ions of Lassa fever (LF) are associated with fatal outcome.

40 One-third of patients had a fatal outcome.

41 n aggressive type of childhood cancer with a fatal outcome.

42 factors associated with severe influenza and fatal outcome.

43 (P = .01) were independently associated with fatal outcome.

44 ; p<0,001) were independent risk factors for fatal outcome.

45 children or between those with and without a fatal outcome.

46 highly aggressive malignant brain tumor with fatal outcome.

47 was reversible in all but one patient with a fatal outcome.

48 P < .001) were independent risk factors for fatal outcome.

49 (IPF) is a progressive clinical syndrome of fatal outcome.

50 l cord and cervical vessels and often have a fatal outcome.

51 1 year after transplantation with a rapidly fatal outcome.

52 ) and respiratory failure with a potentially fatal outcome.

53 transmission of varicella-zoster virus with fatal outcome.

54 ed intracranial pressure may contribute to a fatal outcome.

55 ons in TREX1 experience an earlier onset and fatal outcome.

56 high-risk NB relapses after treatment with a fatal outcome.

57 ication in thrombocytopenia with a potential fatal outcome.

58 had a prenatal or perinatal onset with early fatal outcome.

59 ate that EBOV viremia may be associated with fatal outcome.

60 cases to determine clinical risk factors for fatal outcome.

61 children had bacteremia, and 16 (59%) had a fatal outcome.

62 disorders, hemorrhagic lesions, and frequent fatal outcomes.

63 t account for potential herd immunity or non-fatal outcomes.

64 ed by risk-taking behaviors that can lead to fatal outcomes.

65 d treat suspected malaria all contributed to fatal outcomes.

66 treatment were significantly associated with fatal outcomes.

67 human infections worldwide with potentially fatal outcomes.

68 s airflow, leading to severe and potentially fatal outcomes.

69 tient care, with one associating biases with fatal outcomes.

70 nt between and predictive of recovery versus fatal outcomes.

71 emodynamic instability was not predictive of fatal outcomes.

72 severe neurological diseases, which can have fatal outcomes.

73 nfection can lead to severe disease and even fatal outcomes.

74 and heart damage markers are associated with fatal outcomes.

75 th a higher risk of liver injury or critical/fatal outcomes.

76 to acute respiratory distress syndrome with fatal outcomes.

77 lying most cardiovascular diseases and their fatal outcomes.

78 ncluding anaphylaxis and potentially lead to fatal outcomes.

79 mate HIV mortality and DisMod-MR 2.1 for non-fatal outcomes.

80 g immuno-compromised patients with severe or fatal outcomes.

81 including the proportion of individuals with fatal outcomes.

82 toms but then often leads to more serious or fatal outcomes.

83 nts, of which six (16%) were associated with fatal outcomes.

84 a-glutamyl carboxylase (GGCX) that often has fatal outcomes.

85 en a CAD PRS and incident cardiovascular and fatal outcomes.

86 has been seen historically in patients with fatal outcomes.

87 ogy and dysregulation, which likely leads to fatal outcomes.

88 o quantify health levels associated with non-fatal outcomes.

89 ause severe infections in humans, often with fatal outcomes.

90 e and the specific pathogens associated with fatal outcomes.

91 haviours that lead to relapse and poor, even fatal, outcomes.

92 In swine with fatal outcomes (90 minutes of ischemia), all enzyme leve

93 e and sex, robustly identified patients with fatal outcome (adjusted hazard ratio for log-transformed

94 an emergency setting were at high risk of a fatal outcome after NMBA-induced anaphylaxis.

95 l pneumonia and cardiac injury contribute to fatal outcomes after infection with influenza B virus an

96 entially important mechanism, accounting for fatal outcomes after successful resuscitation in 70% of

97 For PRx, those patients with a fatal outcome also had a higher (more impaired) PRx thro

98 tigation to identify factors associated with fatal outcomes among persons with poliomyelitis in Point

99 angiopoietin 2 is strongly associated with a fatal outcome and could serve as a predictive marker for

100 difference in mean ICP between those with a fatal outcome and functional survivors was only signific

101 icant association (P<.001) was found between fatal outcome and genotype at IL1B (nucleotide position

102 ural evolution is rupture, which often has a fatal outcome and whose diagnosis is part of the patholo

103 e about the characteristics of patients with fatal outcomes and the use of antiviral drug for SFTS.

104 y was designed to identify the predictors of fatal outcomes and to evaluate the effectiveness of anti

105 Associations with disease severity, fatal outcome, and survival were identified using logist

106 ransplantation per se is a risk factor for a fatal outcome, and the indication for reOLT does not app

107 ons to NMBAs, to identify risk factors for a fatal outcome, and to describe management of the cases t

108 d showed high accuracy for the prediction of fatal outcome (area under the curve 0.94).

109 , have been reported to have higher risks of fatal outcomes, associated with higher parasite biomass

110 rsening oxygenation impairment and predicted fatal outcome (AUROC 0.817-0.898).

111 n posture during acute reactions can trigger fatal outcomes, but the impact of allergic reactions on

112 To identify risk factors for fatal outcomes, clinical and epidemiologic data on all h

113 nt in preventing progressive disease and the fatal outcome common in IPF.

114 tially among persons with diabetes, although fatal outcomes declined less among those with type 2 dia

115 sease characterized by arthralgia, with some fatal outcomes described.

116 Patients with fatal outcome displayed higher levels of interleukin (IL

117 and implementation of strategies to prevent fatal outcomes due to cardiovascular disease is vital.

118 had a treatment-related adverse event with a fatal outcome during study treatment.

119 udies (yielding 17 722 incident fatal or non-fatal outcomes during 474 976 person-years at risk), we

120 evelopment of high intracranial pressure and fatal outcome following acute brain injury.

121 strictive anorexia nervosa subtype predicted fatal outcome for anorexia nervosa in males.

122 Reston virus (RESTV) to severe disease with fatal outcomes for EBOV.

123 ) or whether the calculated probability of a fatal outcome from VOD could discriminate responders fro

124 h certain PIDs are at high risk of severe or fatal outcomes from SARS-CoV-2 infections (the causative

125 3, outlet strut fractures (OSFs), often with fatal outcomes, had been reported in 633 BSCC valves (0.

126 oncentrations were higher in patients with a fatal outcome if all in-hospital deaths were considered

127 fections of Elizabethkingia species can have fatal outcomes if not identified and treated properly.

128 fully reversible, TIAN was associated with a fatal outcome in 1 patient.

129 , independent risk factors associated with a fatal outcome in a multivariate analysis were male gende

130 down is associated with severe disease and a fatal outcome in adults with falciparum malaria.

131 in-2 and microRNA-150, was associated with a fatal outcome in adults.

132 esonance imaging (MRI) was associated with a fatal outcome in African children.

133 Conversely, fatal outcome in AGMs was associated with aberrant innat

134 osis, all of which have been associated with fatal outcome in animal models.

135 primary septicemia and was associated with a fatal outcome in both wound infections (relative risk [R

136 most cases pursues an inexorable course with fatal outcome in early childhood.

137 er with multiorgan involvement and a usually fatal outcome in early childhood.

138 accompanies and potentially contributes to a fatal outcome in EHF patients.

139 This cancer leads to a fatal outcome in less than 18 months.

140 solid-organ transplantation, with a related fatal outcome in less than five cases.

141 s of QA and PA in CSF were associated with a fatal outcome in Malawian children with cerebral malaria

142 result in a severe hemorrhagic fever with a fatal outcome in over 50% of human cases.

143 develop a model able to predict the risk of fatal outcome in patients with COVID-19 that could be us

144 The updated model was also useful to predict fatal outcome in patients without respiratory distress a

145 neumonia and subsequent renal failure with a fatal outcome in Saudi Arabia.

146 mozygosity was significantly associated with fatal outcome in the Arizona cohort (OR = 13.2 [95% CI,

147 ed elevated IgA response was associated with fatal outcome in these COVID-19 patients.

148 determine mortality ratios and predictors of fatal outcome in women diagnosed as having anorexia or b

149 We analysed Lassa fever susceptibility and fatal outcomes in 533 cases of Lassa fever and 1,986 pop

150 pectancy (HALE) summarises mortality and non-fatal outcomes in a single measure of average population

151 ore the effectiveness of AAIs for preventing fatal outcomes in anaphylaxis, using information drawn f

152 conorii(pRam18dRGA[AmTrCh]) elicits the same fatal outcomes in animals as its untransformed counterpa

153 may provide vital first-line defense against fatal outcomes in case of an A(H7N9) pandemic.

154 sociated with severe respiratory disease and fatal outcomes in humans.

155 sociated with severe respiratory disease and fatal outcomes in humans.

156 d impaired NO bioactivity is associated with fatal outcomes in malaria.

157 rsistent pulmonary arterial hypertension and fatal outcomes in newborns.

158 is and cardiac dysfunction may contribute to fatal outcomes in newborns.

159 should be implemented to reduce the risk of fatal outcomes in people with OCD.

160 ds the empirical basis for assessment of non-fatal outcomes in the GBD study.

161 ents a large spectrum of manifestations with fatal outcomes in vulnerable people over 70-years-old an

162 nfection caused by Trichosporon inkin with a fatal outcome, in an immunocompetent patient following a

163 at presentation that were associated with a fatal outcome included fever, weakness, dizziness, diarr

164 or the number of deaths from each of the 282 fatal outcomes included in the GBD 2017 list of causes,

165 associated with increased risks of rare but fatal outcomes, including stillbirth and neonatal mortal

166 n of ICP and PRx and their relationship with fatal outcome, indicating a potential early prognostic a

167 g the acute phase of infection, a subsequent fatal outcome is characterized by an increased upregulat

168 This animal model reveals that a fatal outcome is dominated by the host septic response,

169 is between ST/CC groups and risk factors for fatal outcome (logistic regression) were evaluated.

170 s exposed to such drugs, and the potentially fatal outcome make drug-induced long QT syndrome an impo

171 Considering the <2 % rate of anaphylaxis, fatal outcomes, modest predictive value of ST, resource

172 MB and GAG-MS were increased in those with a fatal outcome (n = 3; median, interquartile range: 6.72,

173 score > or =18 was uniformly associated with fatal outcome (n = 8).

174 ficant variant associations with Lassa fever fatal outcomes near GRM7 and LIF in the Nigerian cohort.

175 hylococcus aureus (MRSA) and its potentially fatal outcome necessitate rapid and accurate detection o

176 re horrific diseases with almost universally fatal outcomes; new therapeutics are desperately needed

177 s in the placebo group, three of which had a fatal outcome (nipocalimab: myasthenic crisis; placebo:

178 e collected blood samples from patients with fatal outcomes (non-survivors) and with positive clinica

179 Five (8%) patients with a TEAE had a fatal outcome; none was reported as related to indatuxim

180 A fatal outcome occurred for 2 of the cases.

181 Treatment-emergent adverse events with a fatal outcome occurred in eight (4%) of the 195 patients

182 Treatment-emergent adverse events with a fatal outcome occurred in eight (6%) of 145 patients; no

183 lated treatment-emergent adverse events with fatal outcomes occurred in three (1%) patients in the ap

184 d metastatic progression jointly determine a fatal outcome of cancer.

185 Unpredictable fatal outcome of COVID-19 is attributed to dysregulated

186 roteins upstream of C3a were associated with fatal outcome of COVID-19, supporting a pathological rol

187 n, the organ most frequently involved with a fatal outcome of cryptococcosis.

188 ic transmission of H7N9 and to the severe to fatal outcome of H7N9 infections in humans.

189 ia (CM) is a rare, but severe and frequently fatal outcome of infection with Plasmodium falciparum.

190 subcutaneous spread of S. pyogenes and to a fatal outcome of infection.

191 echanisms underlying the frequently observed fatal outcome of Klebsiella pneumoniae pneumonia in elde

192 e the underlying mechanisms resulting in the fatal outcome of L. major infection in this gene-deficie

193 tobacco carcinogens but have a lower rate of fatal outcome of lung cancer compared with men.

194 The hazard ratio of fatal outcome of lung cancer comparing women with men wa

195 actors, notably underlying comorbidities, on fatal outcome of Middle East respiratory syndrome (MERS)

196 ng us with an immunopathogenic basis for the fatal outcome of SARS-CoV infection in the AC70 mice.

197 l withdrawal syndrome (AWS) is a potentially fatal outcome of severe alcohol dependence that presents

198 d bacterial co-infections contributed to the fatal outcome of this infection.

199 A rapid diagnosis is essential to avoid a fatal outcome of this pathology whose mortality, despite

200 One patient had a fatal outcome of unknown cause, and one patient underwen

201 The fatal outcome of victims after initially successful resu

202 We leverage the temporal range of fatal outcomes of COVID-19 in relation to the onset of s

203 ains of mice, but C3H and FVB/N mice exhibit fatal outcomes of infection.

204 sk Factors Study (GBD) 2017 of non-fatal and fatal outcomes of injury at the national and subnational

205 months postinjury, 133 (19%) patients had a fatal outcome; of those, 88 (78%) died from nonsurvivabl

206 Two adverse events with fatal outcome (one patient with urosepsis in the BRCA co

207 terized by progressive muscle weakness, with fatal outcomes only in a few years after diagnosis.

208 ic discrimination beyond baseline values for fatal outcomes only.

209 Only early management may avoid a fatal outcome or the need for an emergency liver transpl

210 atient subgroup, but was not associated with fatal outcomes or sequelae.

211 95% confidence interval [CI], 1.01-5.01) and fatal outcome (OR, 1.64; 95% CI, 1.01-2.64), respectivel

212 1 were significantly higher in patients with fatal outcome (p <.05, p<.01, respectively), with a sens

213 ne assessment seemed to protect women from a fatal outcome (P<.001).

214 stration of intravenous artesunate may avoid fatal outcomes, particularly in females, older adults, a

215 ures) and the mortality index (the number of fatal outcomes per 10,000 exposures).

216 ephrectomy; thus, a practice with documented fatal outcomes persists.

217 All 31 patients with a fatal outcome received epinephrine in a titrated manner

218 However, the ability of ICP to predict a fatal outcome remained relatively stable over time.

219 scales, we found that VE against severe and fatal outcomes remained above 75% even when nAb titers r

220 What distinguishes fatal from non-fatal outcomes remains largely unknown, yet is key to op

221 d from gammadelta T cells and usually with a fatal outcome, remains largely unknown.

222 o acute respiratory distress syndrome with a fatal outcome reminiscent of human disease.

223 mor mass have a more aggressive course and a fatal outcome risk.

224 actors associated with doxycycline delay and fatal outcome, such as early gastrointestinal symptoms a

225 increased the risk of doxycycline delay and fatal outcome, such as early symptoms of nausea and diar

226 s was found to be a more direct predictor of fatal outcome than clinically observed parasitemia.

227 th type 2 diabetes had smaller reductions in fatal outcomes than controls.

228 city was sufficient to protect mice from the fatal outcome that characterizes HLH-like disease and wa

229 thdrawal may avoid the serious and sometimes fatal outcome that has been observed in this and other s

230 opsy tissues from 22 patients with severe or fatal outcomes to characterize pathology and viral antig

231 Considering fatal and non-fatal outcomes together, dengue was responsible for 1.14

232 SMA, a neuromuscular disorder with an often fatal outcome until recently, with those affected never

233 tion in young mice, while in aged animals, a fatal outcome was dominated by TNF and TGF-beta signalin

234 , a correlation between high viral loads and fatal outcome was observed, emphasizing the importance o

235 ted apnea and hypoxia rather than vice versa Fatal outcome was prevented by timely resuscitation.

236 addition to a strong association with PCP, a fatal outcome was significantly and independently associ

237 Also in patients with EVD, fatal outcome was significantly associated with higher c

238 Patients with severe symptoms and a fatal outcome were older (mean [SD] age, 53.4 [15.1] yea

239 Adverse events with a fatal outcome were reported in 12 patients (8%) in the i

240 Predictors of a fatal outcome were severe infections, particularly in sp

241 Fatal outcomes were associated with irreversible multipl

242 Reductions in fatal outcomes were similar in patients with type 1 diab

243 ANDV-infected HPS patients, of whom 34 had a fatal outcome, were retrospectively studied.

244 living with HIV are at an increased risk of fatal outcome when admitted to hospital for severe COVID

245 Alleles B*67 and B*15 were associated with fatal outcomes, whereas B*07 and B*14 were associated wi

246 combination of these biomarkers classifying fatal outcome with 89% sensitivity and 77% specificity (

247 ogistic model showed high discrimination for fatal outcome with the area under the receiving operatin

248 Four patients with AFLP (12.5%) had a fatal outcome, with a corresponding perinatal mortality

249 sulted in a significantly increased risk for fatal outcome, with a relative increase in mortality of

250 blood of a second endocarditis patient with fatal outcome, with eight control strains from unrelated

251 er Injury Network prospective study having a fatal outcome within 2 years of onset.

252 rative neuromuscular disease that leads to a fatal outcome within 2-5 years, and yet, a precise natur

253 Patients with fatal outcome within 3 days after onset of SAB were excl